Neurocrine Biosciences, Inc. was founded in 1992 and is based in San Diego, California. Neurocrine Biosciences, Inc. engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company develops drugs for endometriosis, anxiety, depression, pain, diabetes, irritable bowel syndrome, insomnia, and other neurological and endocrine related diseases and disorders. Its products in clinical development comprise Elagolix, a Phase II product for Endometriosis; CRF1 Antagonist, a phase II product for mood disorders; CRF2 Peptide Agonist, a phase II drug for Cardiovascular related diseases; CRF1 Antagonist, a Phase I product for treating Mood Disorders and Irritable Bowel Syndrome; and Elagolix, a Phase I product for treating Benign Prostatic Hyperplasia and Uterine Fibroids. The company's research programs include Vesicular Monoamine Transporter 2 Inhibitor for movement disorders and schizophrenia; Glucose Dependent Insulin Secretagogues for type II diabetes; Antiepileptic drugs for epilepsy and bipolar disorder; and GnRH Antagonists for hormone dependent diseases and oncology. It has strategic alliances with GlaxoSmithKline to develop and commercialize CRF antagonists for psychiatric, neurological, and gastrointestinal diseases; and Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize indiplon in Japan.

Cyanotech Corporation was founded in 1983 and is headquartered in Kailua-Kona, Hawaii. Cyanotech Corporation engages in the cultivation, production, and sale of natural products derived from microalgae worldwide. It offers BioAstin natural astaxanthin, a dietary antioxidant for use as a human nutraceutical and functional food ingredient to support and maintain the body's natural inflammatory response, as well as to enhance skin, muscle, and joint health. The company also provides Spirulina Pacifica, a nutrient-rich dietary supplement used for extra energy, as well as used as a strengthened immune system and source of antioxidant carotenoids. It sells its products to manufacturers, formulators, and distributors in the health foods and nutritional supplements markets; and to distributors, retailers, and direct consumers in the form of packaged consumer products. The company sells its products through online, as well as through resellers.

Servier is an independent, French pharmaceutical company which manufactures and sells drugs to combat cardiovascular diseases, such as coronary artery disease, hypertension, and stroke. Cardiovascular drugs account for about two-thirds of the company's annual revenues. It also produces medicines to treat diabetes, venous disease, and cancer. Annually, more than 700 million boxes of drugs are produced by Servier. Its pharmaceutics can be found in 140 countries; 80% of its sales are generated internationally.

NeurogesX, Inc. (NeurogesX) is a biopharmaceutical company focused on developing and commercializing pain management therapies. The Company is assembling a portfolio of pain management product candidates and is developing new therapies based on known chemical entities. Its initial focus is on the management of chronic peripheral neuropathic pain conditions. The Company’s most advanced product candidate, Qutenza, a dermal patch containing a high concentration of synthetic capsaicin, is designed to manage pain associated with peripheral neuropathic pain conditions. The Company submitted to the United States Food and Drug Administration’s (FDA) an new drug application (NDA) for Qutenza for the management of pain associated with postherpetic neuralgia (PHN), in October 2008 which was filed by the FDA in December 2008. The Company's Products include Qutenza, NGX-1998, Acetaminophen Prodrugs (NGX-1576, NGX-9674, NGX-5752) and Opioid Prodrugs (NGX-6052).

GeoPharma, Inc. was founded in 1985 and is headquartered in Largo, Florida. GeoPharma, Inc. is engaged in manufacturing, packaging and distributing private label dietary supplements, generic drugs, and health and beauty products under six of its companies, Innovative Health Products, Inc., Libi Labs, Belcher Pharmaceuticals, Inc., American Antibiotics, LLC and EZ-Med. Innovative Health Products and Libi Labs specialize in the development and manufacture of a range of nutritional supplements and cosmeceuticals. Its subsidiaries include Belcher Pharmaceuticals, Inc., Go2PBM Services, Inc., IHP Marketing, Inc., Breakthrough Marketing, Inc., Belcher Capital Corporation, American Antibiotics, LLC, Libi Labs, Inc., EZ-Med Company (EZ-Med) and Dynamic Health Products, Inc. Effective March 31, 2009, the Company discontinued its Distribution segment, which includes Breakthrough Engineered Nutrition.

Pharming Group N.V. is a Netherlands-based biotechnology company. The Company has facilities both in the Netherlands and the United States. Pharming develops products for the treatment of diseases with significant medical needs, including genetic disorders, diseases associated with the immune system, ageing diseases, and nutritional products. The Company’s technologies include platforms for the production of protein therapeutics and technology and processes for the purification and formulation of these products, as well as technologies in the field of DNA repair via its subsidiary DNage BV. Pharming products under development are divided into three categories: biopharmaceuticals, biomaterials, and bio-nutritionals. Products in the most advanced stage of development and closest to commercialization are Rhucin and human lactoferrin for use in food products. Pharming has several partnerships and collaborations with, inter alia, AgResearch, US Army, Aslan and Schering-Plough.

APP Pharmaceuticals, a company that develops, makes, and markets anesthetics and other injectable drugs. Specializing in generics, APP's critical care products segment includes market-leading general anesthetic Diprivan and blood thinner Heparin. Other product segments focus on injectable oncology treatments and drugs that fight ear, heart, respiratory tract, skin, and sinus infections. APP markets through a direct sales force and often sells through group purchasing organizations to customers that include hospitals, long-term care facilities, and clinics in North America. APP Pharmaceuticals, LLC company is a subsidiary of German medical firm Fresenius.

Chesapeake PERL was founded in 2000. Chesapeake PERL calls a "mini bioreactor" to produce proteins. Using its PERLXpress technology platform, the company mass produces antibodies, enzymes, viral antigens, and other proteins in whole insect larvae. It sells its custom protein development services, as well as some research reagents, to biotech concerns, including drug and diagnostics companies, biotech instrument makers, agricultural companies, and makers of industrial enzymes. It has also received federal grants from the NIH, the US Army, and the US Department of Energy.

Neos Therapeutics makes generic drugs take their time. The contract pharmaceutical manufacturer develops and manufactures branded and generic prescription and OTC pharmaceuticals with an emphasis on time-released formulations. Its products include cold and cough remedies and nutritional supplements. Customers are primarily pharmaceutical distributors and other manufacturers. Neos Therapeutics was slapped hard by the FDA in 2007 for manufacturing unapproved drugs. The action prompted a change in ownership and the company was required to re-file its drug applications in order to resume manufacturing.

Chai-Na-Ta Corp., together with its subsidiaries, engages in growing, processing, and marketing North American ginseng. The company offers ginseng in various forms, such as capsule, slice, tablet, tea, powder, extract, and whole root form, as well as an additive to various consumer products. Ginseng Farming Asian or Korean ginseng (Panax ginseng C.A. Meyer), is a herb indigenous to the mountainous forests of eastern Asia. The North American ginseng (Panax quinquefolius) is a woodland plant native to North America. As of December 31, 2008, the company had under lease 473 acres and owned 270 acres of farmland of which 392 are under ginseng cultivation in Ontario. Sales and Marketing The company sells its products primarily in Hong Kong, China, Canada, and the United States. Subsidiaries The company’s wholly-owned subsidiary, Chai-Na-Ta Farms Ltd. (CNT Farms), carries out the planting, growing, and harvesting of the company’s ginseng crops. CNT Farms also handles the storage of root inventory and manages the distribution of inventory directly to local customers or to customers in the Far East through CNT Trading (Hong Kong) Limited. CNT Farms also carries out crop research. The company through its wholly owned subsidiary, CNT Trading (Hong Kong) Limited (CNT HK), carries out direct marketing, sales, and distribution functions for North American ginseng in Hong Kong for distribution through Asia. CNT HK sells ginseng roots directly to brokers, distributors, and certain customers in the Far East, primarily China. The company through its wholly-owned subsidiary, CNT Nutraceuticals Ltd. (CNTN), operates a showroom in Richmond, British Columbia and carries out direct marketing and sales of graded roots and ginseng-based value-added products to customers in Canada. History The company was founded in 1981. It was formerly known as Chai-Na-Ta Ginseng Products Limited and changed its name to Chai-Na-Ta Corp. in 1994.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.